Abstract
The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 317-323 |
Number of pages | 7 |
Journal | Anti-Cancer Drugs |
Volume | 22 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2011 |
Keywords
- Abdominoperineal resection
- cisplatin
- low anterior resection
- pathological complete response
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research